PIK-90

• Description :

  PIK-90 is a DNA-PK and PI3K inhibitor, which inhibits p110α, p110γ and DNA-PK with IC50s of 11, 18 and 13 nM, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H317, H319

• Target :

  DNA-PK; PI3K

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; PI3K/Akt/mTOR

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/PIK-90.html

• Purity :

  99.70

• Solubility :

  1 M HCl : 100 mg/mL (ultrasonic) |DMSO : 6.67 mg/mL (ultrasonic; adjust pH to 2 with HCl)

• Smiles :

  O=C(NC1=NC2=C(C3=NCCN13)C=CC(OC)=C2OC)C4=CC=CN=C4

• Molecular Formula :

  C18H17N5O3

• Molecular Weight :

  351.36

• Precautions :

  H317, H319

• References & Citations :

  [1]Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125 (4) :733-47.|[2]Niedermeier M, et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009 May 28;113 (22) :5549-57.|[3]Cheng CK, et al. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc Natl Acad Sci U S A. 2012 Jul 31;109 (31) :12722-7.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PI3KC2α; PI3KC2β; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; Vps34

• CAS Number :

  [677338-12-4]